Physician profile
Michael S Ader
NPI 1760477830
$5,127.98
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $721 · 2021: $866 · 2022: $718 · 2023: $850 · 2024: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.30 | 2019-2024 | Skyrizi, Rinvoq, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $513.15 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $422.91 | 2019-2023 | Vemlidy |
| Pfizer INC. | $326.66 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.45 | 2019-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $263.18 | 2019-2024 | Dificid |
| Janssen Biotech, INC. | $208.33 | 2019-2024 | Stelara |
| Shionogi INC | $170.77 | 2019 | |
| Redhill Biopharma INC. | $163.55 | 2020-2023 | Talicia |
| Intercept Pharmaceuticals, INC. | $145.91 | 2019-2023 | Ocaliva |
| Janssen Scientific Affairs, LLC | $117.29 | 2019 | |
| Ucb, INC. | $96.72 | 2019 | |
| Boston Scientific Corporation | $77.94 | 2022-2024 | |
| Organon LLC | $72.24 | 2023-2024 | Renflexis, Hadlima |
| Celgene Corporation | $67.61 | 2021-2024 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $61.57 | 2021-2023 | |
| Qol Medical, LLC | $55.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.58 | 2023 | Cyltezo |
| Evoke Pharma, INC. | $29.47 | 2020-2021 | |
| Ardelyx, INC. | $27.26 | 2022-2023 | Ibsrela |
| Daiichi Sankyo INC. | $27.24 | 2022-2023 | Injectafer |
| Genzyme Corporation | $26.53 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $23.05 | 2024 | Dupixent |
| Lilly USA, LLC | $22.05 | 2024 | Omvoh |
| Exact Sciences Corporation | $21.71 | 2023 | Cologuard Collection Kit |
| Orphalan INC | $21.45 | 2024 | Cuvrior |
| Alnylam Pharmaceuticals INC. | $20.93 | 2020 | |
| Allergan, INC. | $16.38 | 2019 | |
| Pentax of America, INC. | $16.37 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Ironwood Pharmaceuticals, INC | $15.92 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.97 | 2021 | |
| Fresenius Kabi USA, LLC | $14.49 | 2023 | Idacio |
| Cumberland Pharmaceuticals, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.